Biopharmaceutical
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Their lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor being developed for both obstructive and non-obstructive HCM. The company aims to improve treatment options by enhancing speed of onset, depth of gradient response, systolic safety, reversibility, and reducing prescribing complexity. Braveheart Bio is backed by a proven leadership team and strong financial foundation, positioning itself as a high-value player in the rapidly evolving cardiovascular therapeutics space.
Beta · Sourced from candidate reports
Be the first to share your experience with Braveheart Bio.
Your reply helps other candidates know what to expect.
